Decision-analytic model reveals reduced neonatal mortality and morbidity with sFlt-1/PlGF testing in hypertensive pregnancy disorders, indicating improved preterm birth outcomes.
Hypertensive disorders of pregnancy (HDP) affect the incidence of preterm birth. The sFlt-1/PlGF ratio test predicts preeclampsia progression, but its effect on neonatal outcomes is understudied. This study estimated reductions in neonatal mortality and morbidity through sFlt-1/PlGF-guided management for hospitalized patients with HDP. Using a decision-analytic model with PRAECIS and BEACON data and neonatal outcomes from a U.S. cohort of 760,000 infants, outcomes were estimated for patients with HDP at 24–35 weeks' gestation. Results indicated biomarker-guided management was associated with averting 1 death and 75 morbidity cases per 1000 preterm deliveries. sFlt-1/PlGF-guided management could reduce preterm neonatal mortality and morbidity.
No takes yet. Share an insight, caveat, or question.
Duque et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: